Detalhe da pesquisa
1.
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
Circulation
; 148(3): 220-228, 2023 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37191040
2.
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
Circulation
; 148(2): 124-134, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212600
3.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
N Engl J Med
; 385(24): 2252-2263, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34449181
4.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
N Engl J Med
; 384(2): 117-128, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200892
5.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med
; 384(2): 129-139, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200891
6.
Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction - a secondary analysis of TOPCAT.
Am Heart J
; 271: 136-147, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412897
7.
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Diabetes Obes Metab
; 26(1): 191-200, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814928
8.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Ann Intern Med
; 176(12): 1606-1616, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048573
9.
Prevention of cardiorenal damage: importance of albuminuria.
Eur Heart J
; 44(13): 1112-1123, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477861
10.
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Circulation
; 145(6): 437-447, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775784
11.
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
Circulation
; 146(11): 808-818, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603596
12.
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
Kidney Int
; 103(1): 196-206, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36367466
13.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
N Engl J Med
; 383(23): 2219-2229, 2020 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33264825
14.
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Am J Nephrol
; 54(9-10): 370-378, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708857
15.
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Nephrol Dial Transplant
; 38(2): 372-383, 2023 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35451488
16.
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
Diabetes Obes Metab
; 25(2): 407-416, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36193847
17.
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
Diabetes Obes Metab
; 25(6): 1512-1522, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36722675
18.
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
Diabetes Obes Metab
; 25(10): 2989-2998, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37402696
19.
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
J Am Soc Nephrol
; 33(1): 225-237, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732509
20.
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Eur Heart J
; 43(31): 2931-2945, 2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35713973